【摘要】 目的:评估美多巴联合森福罗(盐酸普拉克索)治疗帕金森病(PD)的临床疗效。方法:选择55例PD患者,其中Hoehn-Yahr分级Ⅱ级组19例,Ⅲ级组17例,Ⅳ级组16例,Ⅴ级组3例。各组服药情况:65岁以下患者服用森福罗半年以上疗效不佳者加服美多巴;65岁以上患者服用美多巴片半年以上疗效不佳者,联合森福罗片,联合治疗12周后观察临床疗效。结果:Hoehn-Yahr分级Ⅱ级～Ⅳ级临床疗效明显,Ⅴ级组疗效差。结论:美多巴联合森福罗治疗帕金森病早、中期疗效满意,值得推广应用。更多还原

【Abstract】 Objective: Objective In order to evaluate the Madopar combined Sifrol(Pramipexole Hydrochloride) in treatment of Parkinson ’s disease(PD) clinical curative effect.Methods: 55 cases of PD patients,Hoehn-Yahr grade Ⅱ Group 19 cases,17 cases of grade III,IV group 16 cases,3 cases in grade Ⅴ group.Each medication: patients below 65 years old take Sen led more than half a year of bad effect with Madopar;patients aged over 65 with Madopar tablet for more than half a year of bad effect,combined with Sen Luo tablets,to observe the clinical effect of combined treatment of 12 weeks.Results: The patients of Hoehn-Yahr grade II ～ clinical grade IV obviously curative effect,and the V-grade group difference.Conclusion: Conclusion: Madopar combined Sen Luo treatment of Parkinson’s disease early,mid-term curative effect,it is worthy of popularization and application.更多还原